Core Viewpoint - The research teams from Tsinghua University and Capital Medical University have developed a novel method to bypass the blood-brain barrier using nanoparticles to deliver drugs directly to stroke lesions, potentially overcoming a significant challenge in neurological disease treatment [1][3]. Group 1: Research Findings - The study reveals that the bone marrow within the skull is not a static structure but is connected to the meninges through microchannels, allowing immune cells to bypass the blood-brain barrier and enter the brain [3]. - The research team utilized a minimally invasive injection method to deliver albumin nanoparticles into the skull bone marrow, which were efficiently taken up by immune cells, forming "skull immune cell micro-nanobots" for targeted drug delivery [3][4]. - The nanoparticles demonstrated low systemic exposure, with minimal entry into peripheral blood and major organs, ensuring good biocompatibility and safety [3][4]. Group 2: Clinical Implications - In mouse models of acute ischemic stroke, the new delivery method significantly reduced infarct volume and edema, improved neurological function, and showed long-term benefits in reducing brain atrophy and enhancing survival rates [4]. - An exploratory clinical study involving 20 patients with malignant cerebral artery occlusion indicated that the procedure was well-tolerated, with no severe adverse events reported, and showed positive trends in neurological recovery [4][5]. Group 3: Future Prospects - The research suggests that this delivery pathway could extend beyond drug delivery, potentially integrating with brain-machine interface technologies to facilitate multi-directional exchanges of materials, energy, and information between the brain and artificial systems [5].

Core Insights - A Beijing research team has developed a new method for drug delivery to treat neurological diseases, potentially eliminating traditional oral and intravenous methods [1][2] - The breakthrough involves bypassing the blood-brain barrier, which typically prevents most therapeutic drugs from entering the brain [1] - The new technique utilizes tiny nanoparticles that are injected into the skull, where they are taken up by immune cells and transported directly to the brain's affected areas [1] Group 1 - The research was published in the prestigious journal "Cell" on January 17, highlighting its significance in the field [1] - The method shows promising results in animal experiments for stroke treatment, with significant reductions in brain damage and improved neurological function [1] - The research team includes experts from Beijing Tiantan Hospital and Tsinghua University, indicating a strong collaborative effort [1] Group 2 - Initial exploratory treatments using this technology have been conducted on 20 severe stroke patients, showing positive trends in neurological recovery [2] - This research provides a new, precise drug delivery approach for treating various neurological diseases, including stroke and Alzheimer's disease [2] - The findings suggest a potential shift in treatment paradigms for neurological conditions in the future [2]

Core Viewpoint - The article discusses a groundbreaking method for drug delivery to the central nervous system (CNS) by utilizing calvarial immune cells to bypass the blood-brain barrier (BBB), which has significant implications for treating CNS diseases [4][5][15]. Group 1: Blood-Brain Barrier and Drug Delivery Challenges - The blood-brain barrier (BBB) is crucial for preventing harmful substances from entering the brain but also limits the delivery of most small and large molecule drugs, hindering treatment for CNS diseases [2][7]. - The high failure rate of clinical trials for CNS drugs is primarily due to the inability of most drugs to cross the BBB, leading to insufficient drug accumulation in the brain and poor therapeutic outcomes [7][8]. Group 2: Innovative Drug Delivery Method - A research team from Tsinghua University and Beijing Tiantan Hospital published a study in Cell, demonstrating that drug-loaded nanoparticles can "hijack" calvarial immune cells to deliver drugs to the CNS by utilizing the skull-meninges channel (SMC) to bypass the BBB [4][10]. - The study confirmed that this method significantly improved short-term and long-term outcomes in preclinical stroke models [4][5]. Group 3: Clinical Trial and Safety - A prospective clinical trial (SOLUTION, NCT05849805) was conducted to assess the safety and feasibility of this method in patients with malignant middle cerebral artery infarction (mMCAI), showing that the intracranial injection procedure is simple and does not cause severe complications [13][15]. - The real-world data from this trial highlights the potential for clinical translation of this innovative drug delivery strategy [13][15]. Group 4: Mechanism and Efficacy - The study utilized albumin nanoparticles that exhibit a tendency to be internalized by immune cells, which then migrate to the CNS injury sites, significantly accumulating in neurons at the damaged areas [12]. - The treatment with drug-loaded nanoparticles demonstrated superior efficacy in reducing ischemic infarction and brain edema compared to conventional methods, achieving these effects with only 1/15 of the usual dosage [12].

Core Viewpoint - The increasing trend of young individuals suffering from health issues, particularly viral meningitis, is linked to poor lifestyle habits such as staying up late and excessive smartphone use, raising concerns about the long-term effects on mental and physical health [1][2]. Group 1: Health Impact - In the past month, Ningbo University First Hospital's infection department has admitted 8 cases of meningitis, with an average patient age of 26, and the youngest being only 16 years old [2]. - A 25-year-old patient experienced viral meningitis after prolonged late-night smartphone use, highlighting the risks associated with such habits [3]. - A 30-year-old patient suffered severe consequences, including a significant drop in cognitive function to that of a 3-year-old, due to viral meningitis and encephalitis caused by similar lifestyle choices [5][6]. Group 2: Mechanism of Illness - The relationship between late-night habits and meningitis is explained by the disruption of the blood-brain barrier and weakened immune response, making it easier for pathogens to invade the central nervous system [6][7]. - Long-term late-night behavior can lead to a disordered neuroendocrine system, further diminishing the body's ability to resist infections [7]. Group 3: Symptoms and Prevention - Common symptoms of meningitis include fever, headache, and neck stiffness, with additional signs like nausea and fatigue [9]. - Prevention strategies emphasize maintaining a regular sleep schedule, ensuring 7-8 hours of sleep per night, and practicing good personal hygiene to reduce infection risk [10][11].

Core Viewpoint - Alzheimer's disease (AD) is characterized by the accumulation of β-amyloid protein and hyperphosphorylated tau protein, leading to neuronal dysfunction and cognitive decline. Current treatments only alleviate symptoms without altering disease progression, while emerging therapies face significant challenges [2]. Group 1: Current Treatments and Limitations - Approved therapies for Alzheimer's, such as acetylcholinesterase inhibitors and NMDA receptor antagonists, only provide symptomatic relief and do not modify disease progression [2]. - Anti-Aβ monoclonal antibodies can reduce Aβ plaque burden and slow cognitive decline but have limitations, including low blood-brain barrier (BBB) permeability and ineffectiveness against newly generated Aβ [2]. - Emerging anti-tau therapies also face challenges, including off-target toxicity and poor clinical efficacy [2]. Group 2: Recent Research Developments - A study published by researchers from Sichuan University developed a method called Microglia-Liposome Fusion Extrusion (MiLi-FE) to create microglia-derived nanovesicles that can cross the BBB and co-deliver rapamycin and AR7 to treat Alzheimer's disease [3][4]. - The study confirmed that both macroautophagy and chaperone-mediated autophagy are impaired in Alzheimer's disease model mice, which precedes Aβ accumulation and drives disease progression [4]. Group 3: Mechanism and Efficacy of New Approach - The AR@ENV nanovesicles can effectively penetrate the BBB and target inflammatory sites in the brains of Alzheimer's patients, activating both autophagy pathways to enhance the clearance of Aβ and other toxic protein aggregates [5]. - This dual activation restores protein homeostasis and provides significant neuroprotection, improving neuroinflammation and cognitive deficits in two different Alzheimer's mouse models [5]. Group 4: Future Implications - The combination of synchronized dual autophagy activation and targeted biomimetic delivery positions AR@ENV as a promising candidate for Alzheimer's treatment. The MiLi-FE platform offers a flexible and scalable method for delivering various therapeutic agents to the central nervous system, potentially expanding its applicability to a range of neurological diseases [7].

Core Viewpoint - Sleep deprivation activates the body's inflammatory response, leading to cognitive impairment and increased risk of various diseases [2][3][6]. Group 1: Impact of Sleep Deprivation - A study involving 2,641 participants found that sleeping less than 6 hours triggers systemic inflammation and increases the risk of cognitive impairment [3]. - Sleep deprivation causes a series of inflammatory responses in the brain, releasing pro-inflammatory factors that adversely affect neurons and cognitive functions [3]. - Chronic sleep deprivation leads to oxidative stress and cellular damage, further exacerbating cognitive decline [3][6]. Group 2: Health Risks Associated with Sleep Deprivation - Insufficient sleep and chronic inflammation are linked to various diseases, including metabolic disorders, cancer, and mental health issues [6]. - Research indicates that sleeping less than 6 hours per night for a week can negatively impact metabolism, inflammation, immunity, and stress response [6]. - Prolonged sleep deprivation keeps the body in a state of stress, lowering immune function and increasing disease risk [6]. Group 3: Recommendations for Mitigating Damage - Adults typically need 7-8 hours of sleep per night, while older adults may require 5-7 hours [11]. - To combat sleep deprivation, lifestyle adjustments and medical interventions are recommended, such as increasing sunlight exposure and regular exercise [13]. - A balanced diet rich in anti-inflammatory foods, such as whole grains, deep-sea fish, cruciferous vegetables, and berries, can help reduce inflammation [14][15].

Core Viewpoint - Alzheimer's disease (AD) is a severe neurodegenerative disorder with significant impacts on individuals and society, yet drug development has faced numerous failures despite substantial investments from major pharmaceutical companies [2][3]. Drug Development and FDA Approvals - In June 2021, the FDA accelerated the approval of Aducanumab, developed by Eisai and Biogen, marking the first new drug for Alzheimer's since 2003, although its approval was controversial due to associated risks like ARIA (Amyloid-related Imaging Abnormalities) [3][6]. - Following Aducanumab, the FDA approved two additional antibody drugs targeting Aβ: Donanemab by Eli Lilly and Lecanemab by Eisai and Biogen, both of which also present ARIA-related side effects [3][6]. Denali Therapeutics' Research - Denali Therapeutics published a study in August 2025 on a new antibody transport carrier, ATV cisLALA, which utilizes transferrin receptor (TfR) to enhance brain delivery of anti-Aβ antibodies while mitigating ARIA risks [4][9]. - The ATV cisLALA carrier shows improved distribution in brain tissue compared to traditional Aβ antibodies, which tend to accumulate around blood vessels, potentially triggering inflammatory responses and ARIA [9][11]. Mechanism of Action - Traditional Aβ antibodies enter the brain through cerebrospinal fluid and perivascular spaces, where amyloid deposits are located, leading to inflammation and ARIA. In contrast, the ATV carrier enhances delivery through capillaries, reducing ARIA side effects [11][12]. - Denali's TfR-based approach is not limited to Aβ; the company is also developing therapies targeting tau protein using the same delivery mechanism, aiming to address two key toxic proteins in Alzheimer's simultaneously [11].

Core Viewpoint - The research published by Yale University confirms the presence of T cells in the healthy brains of mice and humans, specifically in the subfornical organ (SFO), indicating that T cells can reside in the brain under normal conditions, contrary to previous beliefs about the blood-brain barrier and immune cell isolation [3][11]. Group 1: Research Findings - The study reveals that T cells in the SFO are enriched and play a crucial role in monitoring gut and fat tissue information, which is essential for regulating feeding and behavior [3][11]. - T cells in the SFO are distinct from those in the meninges, as they express proteins like CXCR6 that allow them to remain in brain tissue and secrete immune signaling proteins such as IFNγ [8][11]. - The research indicates a relationship between dietary habits and the quantity of T cells in the brain, with high-fat diets leading to an increase in T cells in both fat tissue and the brain [8][9]. Group 2: Mechanisms of Interaction - The study demonstrates that fasting increases T cell numbers in the brain while decreasing them in fat tissue, suggesting that dietary intake can dynamically regulate T cell migration to the central nervous system [9][11]. - Antibiotic intervention to deplete gut microbiota resulted in a significant reduction of T cells in the brain, indicating that gut microbiota may influence immune cell homeostasis in the central nervous system [9][11]. - The presence of T cells in the brain is linked to feeding behavior, as T cell-deficient mice took longer to find food when hungry compared to normal mice, highlighting their role in foraging and eating behaviors [9][11].

Core Viewpoint - The research reveals the developmental control mechanism of the meningeal lymphatic system in the brain, highlighting the dynamic regulation by neural activity through specific glial cell subtypes, which provides new insights into the interaction between the nervous and immune systems [3][6][9]. Group 1: Research Findings - The study identifies that neural activity regulates the expression of Vegfc in slc6a11b+ radial astrocytes, which in turn controls the development of mural lymphatic endothelial cells (muLEC) in the meninges [3][5]. - It demonstrates that slc6a11b+ radial astrocytes are the primary source of Vegfc, essential for muLEC development, and that this process is modulated by neural activity [7][9]. - The collaboration between slc6a11b+ radial astrocytes and ccbe1+ fibroblasts ensures that muLEC is restricted to the brain surface, preventing invasion into the brain parenchyma [5][9]. Group 2: Implications for Future Research - The findings suggest that the brain not only processes neural information but also coordinates its microenvironment, providing a new framework for understanding brain-immune interactions [9]. - The research opens avenues for interventions targeting this regulatory network, potentially offering new perspectives on the role of the meningeal lymphatic system in neurodegenerative diseases [9][14]. - It emphasizes the importance of a functional lymphatic network for brain health, indicating that targeting the external lymphatic pathways may enhance treatment efficacy for neurological disorders [14].